EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination

Anass Abbad iD, Brian Lerman, Jordan Ehrenhaus, Brian Monahan, Gagandeep Singh, Adria Wilson, Stefan Slamanig, Ashley Aracena, Neko Lyttle, Jessica R Nardulli, Keith Farrugia, Zain Khalil und 6 weitere

mBio · 14.01.2026 · 17 (1)

DOI: 10.1128/mbio.02901-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 14.01.2026. Verfasst von Anass Abbad und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, ORFDO NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by emerging SARS-CoV-2 subvariants. We assessed neutralizing antibody responses in 56 adults with varied exposure histories following KP.2 vaccination against emerging variants including LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2. While KP.2 vaccination enhanced neutralization against homologous variants, substantial reductions in neutralizing activity were observed against emerging Omicron variants across all exposure groups. Exposure history showed some influence on neutralization breadth, with self-reported vaccination-only participants exhibiting better cross-neutralization compared to individuals with hybrid immunity. Antigenic cartography revealed substantial antigenic distances between KP.2 and emerging variants, highlighting significant immune escape potential that threatens vaccine protection. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, producing variants that escape vaccine-induced immunity. The current work shows that KP.2 monovalent vaccination provides limited protection against antigenically distant Omicron variants (LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2). These findings highlight the ongoing challenge of maintaining vaccine effectiveness against evolving SARS-CoV-2 variants and argue for continuous updating of vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansAdultMaleFemaleMiddle AgedVaccinationSpike Glycoprotein, CoronavirusmRNA VaccinesVaccines, SyntheticYoung AdultAged

Stichwörter der Autor:innen

COVID-19OmicronSARS-CoV-2antigenic cartographymRNA vaccine

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusmRNA VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Anass Abbad, Ana Silvia Gonzalez-Reiche, Weina Sun, Harm van Bakel, Viviana Simon, Florian Krammer

Förderung

  • NCI NIH HHS
  • ORFDO NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute

Zitieren

APA

Abbad, A., Lerman, B., Ehrenhaus, J., Monahan, B., Singh, G., Wilson, A., Slamanig, S., Aracena, A., Lyttle, N., Nardulli, J. R., Farrugia, K., Khalil, Z., Gonzalez-Reiche, A. S., Sordillo, M. E., Sun, W., van Bakel, H., Simon, V., & Krammer, F. (2026). Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination. mBio, 17(1). https://doi.org/10.1128/mbio.02901-25

Vancouver

Abbad A, Lerman B, Ehrenhaus J, Monahan B, Singh G, Wilson A, et al. Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination. mBio. 2026;17(1). doi:10.1128/mbio.02901-25

BibTeX
@article{Abbad2026,
  author = {Abbad, Anass and Lerman, Brian and Ehrenhaus, Jordan and Monahan, Brian and Singh, Gagandeep and Wilson, Adria and Slamanig, Stefan and Aracena, Ashley and Lyttle, Neko and Nardulli, Jessica R and Farrugia, Keith and Khalil, Zain and Gonzalez-Reiche, Ana Silvia and Sordillo, Mia Emilia and Sun, Weina and van Bakel, Harm and Simon, Viviana and Krammer, Florian},
  title = {Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination},
  journal = {mBio},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.1128/mbio.02901-25}
}
Kostenlos starten →